3 Pumps and Valves Maker, Specialty Pharmaceutical Company and Global Automotive Supplier Stocks With a Strong Future Roadmap: Kirloskar Brothers, Ajanta Pharma and UNO Minda
- November 5, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Kirloskar Brothers, Ajanta Pharma and UNO Minda: ROE of 15.2% to 23.3% and FY22 to FY26 revenue CAGR of 10.5% to 23.8%. Prices as of 4 Nov 2026.
Quick Answer
The three pump, specialty drug and auto switch stocks to watch are Kirloskar Brothers, Ajanta Pharma and UNO Minda. Their return on equity ranges from 15.2% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.5% to 23.8%. Ajanta Pharma has the highest return on equity at 23.3%, while UNO Minda has the fastest revenue growth at 23.8% a year. Prices are based on the 4 November 2026 close, and this article is educational, not investment advice.
Pump, specialty drug and auto switch stocks let investors follow companies that serve a growing part of the Indian economy. Kirloskar Brothers, Ajanta Pharma and UNO Minda cover a pumps and valves maker, a specialty pharmaceutical company and an automotive supplier.
This list covers three pump, specialty drug and auto switch stocks with complete current figures: Kirloskar Brothers, Ajanta Pharma and UNO Minda. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pump, Specialty Drug and Auto Switch Stocks?
Pump, specialty drug and auto switch stocks are listed companies that make pumps, valves and hydro systems for water and power projects, sell branded generics in India and many emerging markets, and supply switches, lighting and sensors to vehicle makers. Their earnings depend on water project spending, prescriptions and vehicle output.
Pump, Specialty Drug and Auto Switch Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Kirloskar Brothers | 1,715.7 | 13,186 | 35.0 | 43.0 | 15.2 | 0.10 |
| Ajanta Pharma | 3,316.7 | 41,241 | 36.3 | 36.0 | 23.3 | 0.06 |
| UNO Minda | 1,196.9 | 61,685 | 47.8 | 36.1 | 17.5 | 0.40 |
On valuation, Kirloskar Brothers trades at a P/E below the industry P/E, while Ajanta Pharma and UNO Minda trade above it, which reflects the growth the market already expects. Readers comparing pump, specialty drug and auto switch stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in pump, specialty drug and auto switch stocks can use the coming numbers to test whether growth is holding.
Why Do Pump, Specialty Drug and Auto Switch Stocks Have a Strong Roadmap in India?
Pump, specialty drug and auto switch stocks have a strong roadmap in India because large water and irrigation spending, rising demand for branded medicines and growing vehicle electronics content keep widening the market for these companies.
- Pumps. Water projects need dependable pumping.
- Specialty drugs. Doctors prescribe trusted brands.
- Auto components. Newer vehicles carry more electronics.
Why Kirloskar Brothers Features Among These Pump, Specialty Drug and Auto Switch Stocks
Among the pump, specialty drug and auto switch stocks on this list, Kirloskar Brothers is a Pune-based maker of pumps, valves and hydro systems used in irrigation, water supply, power plants, buildings and industry. It has served customers for over a century.
In the June 2026 quarter, revenue grew 12.5% year on year to Rs 1,120 crore. Revenue rose from Rs 3,090 crore in FY22 to Rs 4,615 crore in FY26, a compound annual growth rate of 10.5%.
Net profit grew from Rs 81.5 crore in FY22 to Rs 361 crore in FY26, which works out to a compound annual growth rate of 45.1%. The company has a return on equity of 15.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 13,186 crore. The stock trades at a P/E of 35.0, below the industry P/E of 43.0.
Roadmap: The company benefits from public spending on water supply, irrigation and urban infrastructure, and it is growing its project and aftermarket business. A deep service network supports repeat orders.
What to watch: Follow order inflows from water and irrigation projects and the share of aftermarket sales.
Why Ajanta Pharma Features Among These Pump, Specialty Drug and Auto Switch Stocks
Among the water, pharma and auto part shares on this list, Ajanta Pharma is a specialty pharmaceutical company that sells branded generics in India and in emerging markets across Asia and Africa, with a focus on ophthalmology, dermatology, cardiology and pain management, and also sells generics in the United States.
The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0.
Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore.
Roadmap: The company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
What to watch: Monitor the pace of new launches in branded markets and the momentum in the United States generics business.
Why UNO Minda Features Among These Pump, Specialty Drug and Auto Switch Stocks
Among the three companies on this list, UNO Minda is a Gurugram-based global automotive supplier of switches, lighting, sensors, alloy wheels, controllers and acoustic products for two-wheelers, passenger vehicles and commercial vehicles.
Revenue rose from Rs 8,376 crore in FY22 to Rs 19,692 crore in FY26, a compound annual growth rate of 23.8%. Net profit grew from Rs 347 crore in FY22 to Rs 1,284 crore in FY26, which works out to a compound annual growth rate of 38.6%.
In the June 2026 quarter, revenue grew 23.6% year on year to Rs 5,563 crore, while net profit rose 2.1% to Rs 316 crore. The company has a return on equity of 17.5%, a debt to equity ratio of 0.40 and a market capitalisation of Rs 61,685 crore. The stock trades at a P/E of 47.8, above the industry P/E of 36.1.
Roadmap: The company is growing in electronics, electric vehicle components and premium products, which carry higher value per vehicle. Acquisitions and joint ventures have widened its technology base.
What to watch: Track electric vehicle component orders, new product launches and international growth.
Kirloskar Brothers vs Ajanta Pharma vs UNO Minda on Key Financials
The table below sets the three pump, specialty drug and auto switch stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Kirloskar Brothers | 3,090 | 4,615 | 10.5% | 361 | 7.8% |
| Ajanta Pharma | 3,457 | 5,625 | 12.9% | 1,056 | 18.8% |
| UNO Minda | 8,376 | 19,692 | 23.8% | 1,284 | 6.5% |
Ajanta Pharma posts the highest return on equity in this group at 23.3%. UNO Minda combines the largest FY26 revenue at Rs 19,692 crore with the fastest revenue growth, a 23.8% compound annual rate. A useful habit with pump, specialty drug and auto switch stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several hydro system, branded generic and lighting stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Kirloskar Brothers | 995 | 1,120 | 12.5% |
| Ajanta Pharma | 1,329 | 1,697 | 27.7% |
| UNO Minda | 4,501 | 5,563 | 23.6% |
Key Risks to Check Before Investing in Pump, Specialty Drug and Auto Switch Stocks
Every theme carries risks that deserve a check before any decision. For these pump, specialty drug and auto switch stocks, the main points are: Long-term water, pharma and auto part shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Government spending. Public project funding can shift between periods.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pump, specialty drug and auto switch stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pump, Specialty Drug and Auto Switch Stocks
Pump, specialty drug and auto switch stocks reward investors who follow demand trends, order books and margins together. Kirloskar Brothers, Ajanta Pharma and UNO Minda each have a clear plan to grow. Based on the 4 November 2026 close, Kirloskar Brothers trades at Rs 1,715.7, Ajanta Pharma at Rs 3,316.7 and UNO Minda at Rs 1,196.9. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pump, specialty drug and auto switch stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pump, specialty drug and auto switch stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pump, specialty drug and auto switch stocks?
Ans. Pump, specialty drug and auto switch stocks are listed companies that make pumps, valves and hydro systems for water and power projects, sell branded generics in India and many emerging markets, and supply switches, lighting and sensors to vehicle makers. Their earnings depend on water project spending, prescriptions and vehicle output. This list looks at three of them, Kirloskar Brothers, Ajanta Pharma and UNO Minda, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.
Which pump, specialty drug and auto switch stocks are covered in this list?
Ans. This list covers Kirloskar Brothers, Ajanta Pharma and UNO Minda. Based on the 4 November 2026 close, Kirloskar Brothers traded at Rs 1,715.7, Ajanta Pharma at Rs 3,316.7 and UNO Minda at Rs 1,196.9. Their return on equity ranges from 15.2% to 23.3%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.5% to 23.8%.
Why do pump, specialty drug and auto switch stocks have a strong future roadmap in India?
Ans. Pump, specialty drug and auto switch stocks have a strong roadmap in India because large water and irrigation spending, rising demand for branded medicines and growing vehicle electronics content keep widening the market for these companies. The main drivers are as follows. Pumps. Water projects need dependable pumping. Specialty drugs. Doctors prescribe trusted brands. Auto components. Newer vehicles carry more electronics. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Kirloskar Brothers performed financially?
Ans. Revenue rose from Rs 3,090 crore in FY22 to Rs 4,615 crore in FY26, a compound annual growth rate of 10.5%. Net profit grew from Rs 81.5 crore in FY22 to Rs 361 crore in FY26, which works out to a compound annual growth rate of 45.1%. In the June 2026 quarter, revenue grew 12.5% year on year to Rs 1,120 crore. The company has a return on equity of 15.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 13,186 crore. The stock trades at a P/E of 35.0, below the industry P/E of 43.0. Looking ahead, the company benefits from public spending on water supply, irrigation and urban infrastructure, and it is growing its project and aftermarket business. A deep service network supports repeat orders.
How has Ajanta Pharma performed financially?
Ans. Revenue rose from Rs 3,457 crore in FY22 to Rs 5,625 crore in FY26, a compound annual growth rate of 12.9%. Net profit grew from Rs 713 crore in FY22 to Rs 1,056 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 27.7% year on year to Rs 1,697 crore, while net profit rose 30.9% to Rs 334 crore. The company has a return on equity of 23.3%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 41,241 crore. The stock trades at a P/E of 36.3, above the industry P/E of 36.0. Looking ahead, the company concentrates on niche therapies where it holds leading positions and has a wide field force in India and Africa. A steady flow of new launches and a debt-free balance sheet support expansion in branded markets.
How has UNO Minda performed financially?
Ans. Revenue rose from Rs 8,376 crore in FY22 to Rs 19,692 crore in FY26, a compound annual growth rate of 23.8%. Net profit grew from Rs 347 crore in FY22 to Rs 1,284 crore in FY26, which works out to a compound annual growth rate of 38.6%. In the June 2026 quarter, revenue grew 23.6% year on year to Rs 5,563 crore, while net profit rose 2.1% to Rs 316 crore. The company has a return on equity of 17.5%, a debt to equity ratio of 0.40 and a market capitalisation of Rs 61,685 crore. The stock trades at a P/E of 47.8, above the industry P/E of 36.1. Looking ahead, the company is growing in electronics, electric vehicle components and premium products, which carry higher value per vehicle. Acquisitions and joint ventures have widened its technology base.
What risks should investors check before buying pump, specialty drug and auto switch stocks?
Ans. Investors should check a few risks before buying pump, specialty drug and auto switch stocks. Government spending. Public project funding can shift between periods. Regulatory approvals. Plant inspections and approvals can affect supplies. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pump, specialty drug and auto switch stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
